Fractalkine program

Kancera is developing two candidate drugs that are targeting the fractalkine axis. Fractalkine, a so-called chemokine, functions as a master regulator of certain specific immune cells and cancer cells. The fractalkine axis consists of the unique ligand-receptor pair CX3CL1-CX3CR1.

Kancera’s two fractalkine-blocking candidate drugs, KAND567 and KAND145, are so called receptor antagonists, i.e. they block the fractalkine receptor CX3CR1. The objective is to block certain specific disease-promoting immune cells and cancer cells.

Kancera’s lead project, KAND567, was initially developed by Astra Zeneca and acquired by Kancera in 2016. At that time, the project was in the preclinical phase and Kancera has thereafter advanced the project into clinical development and completed three phase I studies and two phase IIa studies. As of today, more than 150 healthy subjects and patients have been treated with KAND567, and currently it is being studied in the KANDOVA study, a combined phase Ib/IIa study in ovarian cancer.

KAND145 is Kancera’s second generation fractalkine blocker and has been solely developed by Kancera. KAND145 is a so-called pro drug, i.e. it is metabolized to KAND567 after administration. KAND145 has the same mechanism of action, but improved product properties.

CSO Statement

"We have demonstrated in clinical studies that our CX3CR1 antagonists monitor non-classical monocytes, a form of immune cells known to promote multiple inflammatory diseases and resistant cancers."

Thomas Olin, Chief Scientific Officer, Kancera

Intellectual Properties

Solid IP (Intellectual Properties) sets the foundation for profitable development and commercialization of pharmaceutical drugs. Kancera’s IP strategy relies on two main components – patent protection and market exclusivity through data protection. IP development is an integrated component of Kancera’s research and development.

The IP protection for KAND567 and KAND145 is based on four patent families and basis for data exclusivity according to the table below:

IP overview for KAND567 and KAND145


Type of IPTerritoriesTermStatus
Chemical structureMajor markets12039Granted in US, EU and South Africa
Review process ongoing in other markets
Manufacturing process2Major markets 2039Granted in US, Japan and South Africa
Review process ongoing in other markets
Data exclusivityUS, EU5–10 years from market approvalApplication to be submitted after market approval


Type of IPTerritoriesTermStatus
Manufacturing process2Major markets2039Granted in US, Japan and South Africa
Review process ongoing in other markets
Chemical structure
(2 patent families)
US, China, Japan, EU-big 442027Granted
Data exclusivityUS, EU5–10 years from market approvalApplication to be submitted after market approval

1 US, Canada, EU, Asia
2 One patent family covers the manufacturing processes for both KAND145 and KAND567
3 Divisional application from manufacturing process
4 EU-big 4 = Germany, France, UK and Italy
Source: Kancera

Selected Publications

Fractalkine axis in cardiovascular diseases

Review that summarizes clinical research addressing the pathology driving role of fractalkine axis in cardiovascular disease and the potential of the Kancera drug candidate KAND567

Shu Xian Loh, Yasemin Ekinci, Luke Spray, Visvesh Jeyalan, Thomas Olin, Gavin Richardson, David Austin, Mohammad Alkhalil, Ioakim Spyridopoulos.
Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease

In a study with 480 heart attack patients, Kancera's partner Professor Ioakim Spyridopoulos and his research group have shown the potential for the Fractalkine blocker KAND567 to prolong life after an acute heart attack.

Spray L, Park C, Cormack S, Mohammed A, Panahi P, Boag S, Bennaceur K, Sopova K, Richardson G, Stangl VM, Rech L, Rainer PP, Ramos GC, Hofmann U, Stellos K, Spyridopoulos I.
The Fractalkine Receptor CX3CR1 Links Lymphocyte Kinetics in CMV-Seropositive Patients and Acute Myocardial Infarction With Adverse Left Ventricular Remodeling.

Fraktalkine axis in oncology

Positive research results for Kancera's Fractalkine blockers may pave the way for new treatment for ovarian cancer

Lehto J, Huguet Ninou A, Chioureas D, Jonkers J, Gustafsson NMS.
Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.

Study in primary samples from cancer with progressive disease show that KAND567 has capacity to kill leukemic cells by blocking specific immune cells in the leukemia microenvironment.

Mohammad Hojjat-Farsangi MSc,PhD , Wen Zhong Ms.C, Tom Mulder MD PhD, Ann Svensson Ms.C, Jeanette Lundin MD PhD, Marzia Palma MD PhD, Johan Schultz PhD, Thomas Olin PhD, Bjorn Wahlin MD PhD, Anders Osterborg MD PhD, Parviz Kokhaei PhD, Hakan Mellstedt MD PhD
A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells